Total Payments
$710.95
2020 Payments
$97.22
Companies
13
Transactions
45
Medicare Patients
6,184
Medicare Billing
$339,102
Payment Breakdown by Category
Food & Beverage$710.95 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $710.95 | 45 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $203.17 | 15 | $0 (2018) |
| Janssen Pharmaceuticals, Inc | $122.60 | 3 | $0 (2020) |
| GlaxoSmithKline, LLC. | $100.56 | 6 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $69.08 | 5 | $0 (2018) |
| Merck Sharp & Dohme Corporation | $58.51 | 4 | $0 (2017) |
| PFIZER INC. | $37.03 | 3 | $0 (2018) |
| Astellas Pharma US Inc | $26.23 | 2 | $0 (2018) |
| Amgen Inc. | $21.85 | 2 | $0 (2018) |
| BOSTON SCIENTIFIC CORPORATION | $16.66 | 1 | $0 (2018) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $15.81 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2020 | $97.22 | 1 | Janssen Pharmaceuticals, Inc ($97.22) |
| 2018 | $225.57 | 17 | GlaxoSmithKline, LLC. ($41.31) |
| 2017 | $388.16 | 27 | Novo Nordisk Inc ($176.62) |
All Payment Transactions
45 individual payment records from CMS Open Payments — Page 2 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/30/2017 | Merck Sharp & Dohme Corporation | JANUVIA (Drug), JANUMET, BELSOMRA | Food and Beverage | In-kind items and services | $11.44 | General |
| Category: ENDOCRINOLOGY | ||||||
| 10/23/2017 | Novo Nordisk Inc | Saxenda (Drug) | Food and Beverage | In-kind items and services | $12.66 | General |
| Category: Obesity | ||||||
| 10/02/2017 | Novo Nordisk Inc | Victoza (Drug) | Food and Beverage | In-kind items and services | $17.60 | General |
| Category: Diabetes | ||||||
| 09/25/2017 | GlaxoSmithKline, LLC. | BREO (Drug), INCRUSE | Food and Beverage | In-kind items and services | $17.97 | General |
| Category: RESPIRATORY | ||||||
| 09/18/2017 | Merck Sharp & Dohme Corporation | ZOSTAVAX (Biological), PNEUMOVAX 23, GARDASIL9 | Food and Beverage | In-kind items and services | $16.09 | General |
| Category: VACCINE | ||||||
| 08/28/2017 | Novo Nordisk Inc | Victoza (Drug) | Food and Beverage | In-kind items and services | $18.78 | General |
| Category: Diabetes | ||||||
| 08/21/2017 | Novo Nordisk Inc | Tresiba (Drug) | Food and Beverage | In-kind items and services | $15.06 | General |
| Category: Diabetes | ||||||
| 07/31/2017 | Janssen Pharmaceuticals, Inc | XARELTO (Drug), INVOKANA, INVOKAMET | Food and Beverage | In-kind items and services | $11.28 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 07/24/2017 | Novo Nordisk Inc | Victoza (Drug) | Food and Beverage | In-kind items and services | $19.11 | General |
| Category: Diabetes | ||||||
| 07/10/2017 | GlaxoSmithKline, LLC. | ANORO (Drug), INCRUSE, LEVITRA | Food and Beverage | In-kind items and services | $20.98 | General |
| Category: RESPIRATORY | ||||||
| 06/19/2017 | Novo Nordisk Inc | Saxenda (Drug) | Food and Beverage | In-kind items and services | $11.54 | General |
| Category: Obesity | ||||||
| 06/05/2017 | Novo Nordisk Inc | Xultophy 100/3.6 (Drug) | Food and Beverage | In-kind items and services | $12.74 | General |
| Category: Diabetes | ||||||
| 04/10/2017 | Novo Nordisk Inc | Saxenda (Drug) | Food and Beverage | In-kind items and services | $13.08 | General |
| Category: Obesity | ||||||
| 02/27/2017 | AstraZeneca Pharmaceuticals LP | BEVESPI AEROSPHERE (Drug) | Food and Beverage | In-kind items and services | $13.26 | General |
| Category: Respiratory | ||||||
| 02/13/2017 | Novo Nordisk Inc | Saxenda (Drug) | Food and Beverage | In-kind items and services | $14.26 | General |
| Category: Obesity | ||||||
| 02/06/2017 | Merck Sharp & Dohme Corporation | ZOSTAVAX (Biological), PNEUMOVAX 23, GARDASIL9 | Food and Beverage | In-kind items and services | $11.31 | General |
| Category: VACCINE | ||||||
| 01/30/2017 | AstraZeneca Pharmaceuticals LP | BEVESPI AEROSPHERE (Drug) | Food and Beverage | In-kind items and services | $15.25 | General |
| Category: Respiratory | ||||||
| 01/16/2017 | Novo Nordisk Inc | Saxenda (Drug) | Food and Beverage | In-kind items and services | $10.99 | General |
| Category: Obesity | ||||||
| 01/16/2017 | Novo Nordisk Inc | Saxenda (Drug) | Food and Beverage | In-kind items and services | $0.50 | General |
| Category: Obesity | ||||||
| 01/09/2017 | Novo Nordisk Inc | Victoza (Drug), Tresiba | Food and Beverage | In-kind items and services | $13.91 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 22 | 1,319 | 1,785 | $330,498 | $74,881 |
| 2022 | 19 | 1,333 | 1,785 | $329,513 | $73,503 |
| 2021 | 21 | 1,711 | 2,132 | $341,088 | $94,121 |
| 2020 | 24 | 1,821 | 2,187 | $304,258 | $96,598 |
Total Patients
6,184
Total Services
7,889
Medicare Billing
$339,102
Procedure Codes
86
All Medicare Procedures & Services
86 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 285 | 539 | $151,459 | $24,617 | 16.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 245 | 422 | $84,400 | $18,161 | 21.5% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 141 | 141 | $20,304 | $10,689 | 52.6% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 149 | 149 | $11,175 | $4,898 | 43.8% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2023 | 13 | 13 | $7,384 | $3,658 | 49.5% |
| G0446 | Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes | Office | 2023 | 65 | 65 | $3,770 | $1,776 | 47.1% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 70 | 70 | $20,160 | $1,654 | 8.2% |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | Office | 2023 | 77 | 77 | $3,311 | $1,538 | 46.5% |
| 90732 | Pneumococcal vaccine, 23-valent | Office | 2023 | 11 | 11 | $2,937 | $1,439 | 49.0% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 60 | 60 | $2,520 | $1,199 | 47.6% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 19 | 19 | $11,647 | $982.94 | 8.4% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2023 | 13 | 18 | $2,106 | $803.88 | 38.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 16 | 18 | $2,268 | $780.77 | 34.4% |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | Office | 2023 | 28 | 28 | $1,624 | $754.60 | 46.5% |
| G0009 | Administration of pneumococcal vaccine | Office | 2023 | 16 | 16 | $1,200 | $525.92 | 43.8% |
| 69210 | Removal of impacted ear wax | Office | 2023 | 14 | 15 | $1,590 | $522.33 | 32.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 17 | 27 | $864.00 | $304.73 | 35.3% |
| 90471 | Administration of vaccine | Office | 2023 | 14 | 16 | $608.00 | $210.00 | 34.5% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 14 | 15 | $480.00 | $173.60 | 36.2% |
| 81002 | Urinalysis, manual test | Office | 2023 | 26 | 30 | $210.00 | $102.30 | 48.7% |
| 93005 | Routine electrocardiogram (ecg) using at least 12 leads with tracing | Office | 2023 | 14 | 14 | $210.00 | $67.68 | 32.2% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2023 | 12 | 22 | $270.56 | $23.12 | 8.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 289 | 524 | $148,816 | $24,605 | 16.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 282 | 463 | $93,063 | $20,490 | 22.0% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2022 | 163 | 167 | $20,374 | $11,366 | 55.8% |
About Dr. Michael Raguso-Failla, MD
Dr. Michael Raguso-Failla, MD is a Family Medicine healthcare provider based in Little Egg Harbor, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1497837744.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Raguso-Failla, MD has received a total of $710.95 in payments from pharmaceutical and medical device companies, with $97.22 received in 2020. These payments were reported across 45 transactions from 13 companies. The most common payment nature is "Food and Beverage" ($710.95).
As a Medicare-enrolled provider, Raguso-Failla has provided services to 6,184 Medicare beneficiaries, totaling 7,889 services with total Medicare billing of $339,102. Data is available for 4 years (2020–2023), covering 86 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Little Egg Harbor, NJ
- Active Since 10/19/2006
- Last Updated 08/26/2024
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1497837744
Products in Payments
- Victoza (Drug) $98.94
- INVOKANA (Drug) $97.22
- ANORO (Drug) $82.59
- Saxenda (Drug) $63.03
- BEVESPI AEROSPHERE (Drug) $43.40
- JANUVIA (Drug) $31.11
- Tresiba (Drug) $28.46
- ZOSTAVAX (Biological) $27.40
- MYRBETRIQ (Drug) $26.23
- SYMBICORT (Drug) $25.68
- XARELTO (Drug) $25.38
- ELIQUIS (Drug) $23.29
- BREO (Drug) $17.97
- WATCHMAN (Device) $16.66
- SPIRIVA (Drug) $15.81
- TRULICITY (Drug) $14.21
- CHANTIX (Drug) $13.74
- FLUZONE HIGH-DOSE (Drug) $13.51
- Xultophy 100/3.6 (Drug) $12.74
- BYSTOLIC (Drug) $11.73
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.